Полное описание

High-Risk IV Medications in Special Patient Populations : сборник / edited by Sandra Kane-Gill, Joseph Dasta. - London : Springer, 2011. - on-line. - URL: http://dx.doi.org/10.1007/978-0-85729-606-1. - Загл. с экрана. - ISBN 978-0-85729-606-1. - Текст : электронный.
Содержание:
Anesthetic agents (general, inhaled, intravenous) -- Propofol, ketamine, etc -- Anti-infectives -- aminoglycosides, vancomycin, drotrecogin, amphotericin products -- inhaled agents -- Anticoagulants agents -- unfractionated heparin, low molecular weight heparins, fondaparinux, lepirudin, argatroban, bivalrudin, abciximab, eptifibatide, tirofiban -- Thrombolytics –reteplase, tenecteplase, streptokinase, urokinase, alteplase -- Cardiac Drugs -- Adrenergic agents -- dopamine, dobutamine, vasopressin, , nitroglycerin, nitroprusside epinephrine, norepinepherine, phenylepherine -- Adrenergic antagonists -- Propranolol, diltiazem, verapamil, esmolol, labetalol, clevidipine -- Antidyrrhthmics -- amiodarone, lidocaine, procainamide -- Inotropic agents -- milrinone, amrinone, isoproterenol, niseritide, digoxin -- Prostanoids -- Epoprostenol, iloprost, treprostenil -- Electrolytes -- Potassium, magnesium, sodium chloride (hypertonic), cardioplegic solutions -- Hypoglycemics -- Insulin and oral agents -- Neuromuscular blocking agents -- vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine -- Opioids (IV, oral) -- Remifentanyl, fentanyl , morphine, hydromorphone, meperidine -- Sedatives (IV, oral and transdermal) -- lorazepam, midazolam, diazepam, propofol, dexmedetomidine -- Information for Each Drug -- Propofol -- Normal -- Obese -- Renal Dysfunction -- CrCL -- Dialysis (HD, CRRT) -- Liver Dysfunction -- Recommendations for Safe Use.

ГРНТИ	УДК
61.45	615.015.3

Рубрики:
pharmacy
medicine
anesthesiology
emergency medicine
critical care medicine
internal medicine
medicine & Public Health
intensive / Critical Care Medicine
internal Medicine
emergency Medicine
anesthesiology
pharmacy

Аннотация: Critically ill patients are at risk for a higher frequency and severity of adverse drug events (ADEs), and special patient populations of the critically ill – requiring for instance individualized dosing due to non-average weight, hepatic or renal dysfunction, extracorporeal circulation devices, advanced age, pharmacogenetic alterations, hemodynamic instability, or therapeutic hypothermia – are particularly challenging. A contributing factor to this is the use of high-risk medications with many administered intravenously (IV). Hypervigilant monitoring of high-risk medications is still essential to prevent patient harm, especially in populations that have dosing challenges, hence, regulatory bodies internationally require active institutional surveillance of high-risk medications. These dosing challenges are a great safety concern, since there is considerable risk of unwanted adverse drug events from overdosing or therapeutic inefficacy from underdosing. High-Risk IV Medications in Special Patient Populations reviews high-risk IV medication dosage considerations for special patient populations and discusses the safety concerns of these medications to aid the clinician in cautious monitoring.  The authors provide clinicians with tools to minimize adverse drug events with IV high-risk medications, while maximizing the beneficial clinical effects of these drugs, thus making this book essential reading for all involved with the care of critically ill patients. .
Доп. точки доступа:
Kane-Gill, S.\editor.\
Dasta, J.\editor.\

http://dx.doi.org/10.1007/978-0-85729-606-1

Держатели документа:
Государственная публичная научно-техническая библиотека России : 123298, г. Москва, ул. 3-я Хорошевская, д. 17 (Шифр в БД-источнике (KATBW): -932324968)

Шифр в сводном ЭК: 405ce4ef9a26f0d0b817f388dcded68a

Просмотр издания